Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $2.0 million.

  • Tg Therapeutics' Other Non-Current Liabilities fell 3621.59% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 3621.59%. This contributed to the annual value of $3.8 million for FY2024, which is 96162.46% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Other Non-Current Liabilities is $2.0 million, which was down 3621.59% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Other Non-Current Liabilities ranged from a high of $3.8 million in Q4 2024 and a low of $243000.0 during Q4 2022
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $2.0 million (2025), whereas its average is $1.7 million.
  • Per our database at Business Quant, Tg Therapeutics' Other Non-Current Liabilities plummeted by 6162.05% in 2021 and then surged by 96162.46% in 2024.
  • Over the past 5 years, Tg Therapeutics' Other Non-Current Liabilities (Quarter) stood at $360000.0 in 2021, then plummeted by 32.5% to $243000.0 in 2022, then surged by 46.91% to $357000.0 in 2023, then skyrocketed by 961.62% to $3.8 million in 2024, then plummeted by 48.23% to $2.0 million in 2025.
  • Its Other Non-Current Liabilities stands at $2.0 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.2 million for Q1 2025.